Incidence of Prosthesis-Patient Mismatch in Valve-in-Valve with a Supra-Annular Valve.

Alwan, Louhai; Ruge, Hendrik; Krane, Markus; Prinzing, Anatol; Noebauer, Christian; Lange, Rüdiger; Erlebach, Magdalena

doi:10.1055/s-0042-1742755

journal article

Title:: Incidence of Prosthesis-Patient Mismatch in Valve-in-Valve with a Supra-Annular Valve.
Document type:: Journal Article
Author(s):: Alwan, Louhai; Ruge, Hendrik; Krane, Markus; Prinzing, Anatol; Noebauer, Christian; Lange, Rüdiger; Erlebach, Magdalena
Abstract:: BACKGROUND: Transcatheter aortic valve replacement (TAVR) for a degenerated surgical bioprosthesis (valve-in-valve [ViV]) has become an established procedure. Elevated gradients and patient-prosthesis mismatch (PPM) have previously been reported in mixed TAVR cohorts. We analyzed our single-center experience using the third-generation self-expanding Medtronic Evolut R prosthesis, with an emphasis on the incidence and outcomes of PPM. METHODS: This is a retrospective analysis of prospectively collected data from our TAVR database. Intraprocedural and intrahospital outcomes are reported. RESULTS: Eighty-six patients underwent ViV-TAVR with the Evolut R prosthesis. Mean age was 75.5 ± 9.5 years, 64% were males. The mean log EuroScore was 21.6 ± 15.7%. The mean time between initial surgical valve implantation and ViV-TAVR was 8.8 ± 3.2 years. The mean true internal diameter of the implanted surgical valves was 20.9 ± 2.2 mm. Post-AVR, 60% had no PPM, 34% had moderate PPM, and 6% had severe PPM. After ViV-TAVR, 33% had no PPM, 29% had moderate, and 39% had severe PPM. After implantation, the mean transvalvular gradient was reduced significantly from 36.4 ± 15.2 to 15.5 ± 9.1 mm Hg (p < 0.001). No patient had more than mild aortic regurgitation after ViV-TAVR. No conversion to surgery was necessary. Estimated Kaplan-Meier survival at 1 year for all patients was 87.4%. One-year survival showed no significant difference according to post-ViV PPM groups (p = 0.356). CONCLUSION: ViV-TAVR using a supra-annular valve resulted in low procedural and in-hospital complication rates. However, moderate or severe PPM was common, with no influence on short-term survival. PPM may not be a suitable factor to predict survival after ViV-TAVR.
Journal title abbreviation:: Thorac Cardiovasc Surg
Year:: 2023
Journal volume:: 71
Journal issue:: 8
Pages contribution:: 632-640
Fulltext / DOI:: doi:10.1055/s-0042-1742755
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/35255516
Print-ISSN:: 0171-6425
TUM Institution:: Klinik für Herz- und Gefäßchirurgie (DHM) (Prof. Lange)
BibTeX

Occurrences:

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Lehr- und Forschungskooperationen mit den Kliniken und Instituten am Deutschen Herzzentrum Klinik für Herz- und Gefäßchirurgie (DHM) (Prof. Krane)2023